Skip to main content
TipRanks
Go Ultimate75% OFF

Prostatype Genomics AB (PROGEN) AI Stock Analysis

0 Followers
SE:PROGEN

Prostatype Genomics AB

(Nasdaq OMX AB:PROGEN)

Select Model
Rating:39Underperform
Price Target:SEK 0.10â–²(13.48% Upside)
Action:reiterated
Date:09/30/26

Prostatype Genomics scores near the bottom of the range. The dominant issue is financial fragility: negligible revenue, negative gross profit, persistent multi-year losses and an equity base of roughly SEK 6.5 million against approximately SEK 21 million of annual cash burn, pointing to an urgent funding need and likely shareholder dilution. Technicals reinforce the caution, with the price well below all major moving averages and negative MACD momentum. Valuation provides no cushion given negative earnings and no dividend. Modest offsets — a debt-free balance sheet and reduced cash burn — keep the score slightly above the floor, but this remains a highly speculative, high-risk profile dependent on commercial adoption of its prostate cancer test and successful refinancing.

Positive Factors
Focused precision-medicine businessThe company operates in a focused precision-medicine niche, using genomic and biomarker analysis to support prostate-cancer treatment decisions. A specialized diagnostic offering can create durable clinical relevance if adoption expands, because risk assessment and treatment guidance are recurring healthcare needs.
Negative Factors
Severe unprofitabilityDeeply negative gross, operating, and net margins show that current revenue does not cover the economics of the business. Unless pricing, delivery economics, or operating efficiency improve materially, persistent losses will constrain reinvestment and weaken the path to sustainable profitability.

Prostatype Genomics AB (PROGEN) vs. iShares MSCI Sweden ETF (EWD)

-100%-50%0%50%100%150%200%250%SE:PROGEN-62.13%EWD+8.63%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
SEK 64.02M
Dividend Yield
―
Average Volume (3M)
7.59M
Price to Earnings (P/E)
-0.2
Beta (1Y)
-0.38
Revenue Growth
143.94%
EPS Growth
70.95%
Country
Sweden
Employees
7
Sector
Healthcare
Sector Strength
51
Industry
Medical - Diagnostics & Research

Prostatype Genomics AB Business Overview & Revenue Model

Company Description

Prostatype Genomics AB focuses on creating, marketing, and selling sophisticated prognostic gene tests. Their primary offering, the Prostatype Test System, combines genetic expression data with key clinical measurements such as PSA levels, Gleason Sc...

Prostatype Genomics AB Financial Statement Overview

Summary

Financials are extremely weak. Revenue is immaterial at roughly SEK 1.0 million TTM, gross profit is negative (about -SEK 27.8 million), and net losses of SEK 38–45 million have persisted for four consecutive years. Shareholders' equity has collapsed to about SEK 6.5 million against an annual cash burn of roughly SEK 21 million, implying only a few months of runway and a high probability of dilutive refinancing. The only meaningful positives are the absence of interest-bearing debt and a narrowing cash burn versus 2024, which prevents a bottom-of-scale score but does not offset severe going-concern risk.

Income Statement

5Very Negative

Balance Sheet

14Very Negative

Cash Flow

6Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue1.01M594.00K199.00K1.36M683.00K10.00K
Gross Profit-27.83M-37.62M1.92M3.73M683.00K2.51M
EBITDA-34.16M-36.89M-37.40M-38.02M-26.79M-15.46M
Net Income-37.90M-44.50M-41.05M-41.44M-29.09M-15.63M
Balance Sheet
Total Assets39.91M50.86M41.97M49.22M30.95M40.20M
Cash, Cash Equivalents and Short-Term Investments392.00K9.07M9.42M2.68M11.49M20.33M
Total Debt05.30M67.00K11.67M867.00K1.27M
Total Liabilities33.36M24.33M8.50M24.55M4.80M4.30M
Stockholders Equity6.55M26.53M33.47M24.67M26.15M35.91M
Cash Flow
Free Cash Flow-20.96M-24.06M-52.57M-37.70M-27.69M-18.58M
Operating Cash Flow-20.90M-23.80M-44.71M-29.14M-27.69M-16.08M
Investing Cash Flow-12.27M-13.36M-8.36M-8.57M0-2.50M
Financing Cash Flow20.64M36.83M59.75M28.91M18.85M23.05M

Prostatype Genomics AB Technical Analysis

Technical Analysis SentimentNegative
Last Price0.09

Price Trends

50DMA0.11Negative
100DMA0.13Negative
200DMA0.22Negative

Market Momentum

MACD-0.00Positive
RSI39.44Neutral
STOCH33.99Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:PROGEN, the sentiment is Negative. The current price of 0.09 is below the 20-day moving average (MA) of 0.10, below the 50-day MA of 0.11, and below the 200-day MA of 0.22, indicating a bearish trend. The MACD of -0.00 indicates Positive momentum. The RSI at 39.44 is Neutral, neither overbought nor oversold. The STOCH value of 33.99 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:PROGEN.

Prostatype Genomics AB Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

SE:PROGEN against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SE:DVYSRSE:DVYSR66NeutralSEK 1.05B40.99――4.49%―
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
SE:IMMNOVSE:IMMNOV46NeutralSEK 139.62M-0.43-215.44%―148.66%66.30%
SE:BIOVIC.BSE:BIOVIC.B41NeutralSEK 86.64M-1.21-75.51%―56.06%63.95%
SE:QLINEASE:QLINEA41NeutralSEK 215.07M-1.31-48.10%―33.26%90.73%
SE:PROGENSE:PROGEN39UnderperformSEK 64.02M-0.17-229.18%―143.94%70.95%
SE:ACARIXSE:ACARIX30UnderperformSEK 191.04M-4.84-96.06%―40.61%32.63%

* Healthcare Sector Average

Performance Comparison

0%100%200%SE:PROGENSE:IMMNOVSE:QLINEASE:ACARIXSE:BIOVIC.BSE:DVYSRDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
SE:PROGEN and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SE:PROGENProstatype Genomics AB0.09-0.13-58.80%
SE:IMMNOVImmunovia AB0.04-0.14-77.71%
SE:QLINEAQ-linea AB11.15-13.80-55.31%
SE:ACARIXAcarix AB0.16-0.14-47.19%
SE:BIOVIC.BBiovica International AB Class B0.30-0.27-47.18%
SE:DVYSRDevyser Diagnostics AB60.00-51.00-45.95%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 30, 2026